Cargando…

Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination

The global COVID-19 vaccination had an undeniable influence on the pandemic management, despite of having reported rare but life-threatening side-effects of vaccines. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare autoimmune complication determined by thrombocytopenia and thromb...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaheri, Hamidreza, Kiani, Arda, Afaghi, Siamak, Rahimi, Fatemehsadat, Banitorfi, Mohammadhossein, Norozi, Amirmohammad Kazemzadeh, Hashemi, Samaneh, Abedini, Atefeh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: UMF “Gr. T. Popa” Iasi Publishing House 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769072/
https://www.ncbi.nlm.nih.gov/pubmed/36628165
http://dx.doi.org/10.22551/2022.37.0904.10222
_version_ 1784854308256219136
author Zaheri, Hamidreza
Kiani, Arda
Afaghi, Siamak
Rahimi, Fatemehsadat
Banitorfi, Mohammadhossein
Norozi, Amirmohammad Kazemzadeh
Hashemi, Samaneh
Abedini, Atefeh
author_facet Zaheri, Hamidreza
Kiani, Arda
Afaghi, Siamak
Rahimi, Fatemehsadat
Banitorfi, Mohammadhossein
Norozi, Amirmohammad Kazemzadeh
Hashemi, Samaneh
Abedini, Atefeh
author_sort Zaheri, Hamidreza
collection PubMed
description The global COVID-19 vaccination had an undeniable influence on the pandemic management, despite of having reported rare but life-threatening side-effects of vaccines. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare autoimmune complication determined by thrombocytopenia and thrombosis propensity in the circulatory system. The activation of antibodies against platelet factor-4 (PF-4) which mimics the heparin-induced thrombocytopenia (HIT) characteristic is the main known pathogenicity of the disease. Herein, we reported a case of VITT in a middle-aged woman with no previous history of thrombophilia or other medical conditions who presented with thrombosis of the left superficial femoral artery 3-days after receiving the second dose of inactivated BBIBP-CorV (Sinopharm) vaccine. The patient underwent bypass vascular surgery and received none-heparin anticoagulation consistent with high-dose intravenous immunoglobin. Eight days after the discharge, she was subsequently referred to our center with the presentation of sub-massive pulmonary thromboembolism in spite of receiving the prophylactic anticoagulants during follow-up period. Details on side-effects of COVID-19 vaccines, specifically the inactivated ones are yet to be fully ascertained. Clinicians should consider the history of COVID-19 vaccines in thromboembolism patients who do not have well-acknowledged risk factors. Further studies about the necessity of prophylactic anticoagulants and clinical judgment for receiving other vaccines in such patients are required.
format Online
Article
Text
id pubmed-9769072
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher UMF “Gr. T. Popa” Iasi Publishing House
record_format MEDLINE/PubMed
spelling pubmed-97690722023-01-09 Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination Zaheri, Hamidreza Kiani, Arda Afaghi, Siamak Rahimi, Fatemehsadat Banitorfi, Mohammadhossein Norozi, Amirmohammad Kazemzadeh Hashemi, Samaneh Abedini, Atefeh Arch Clin Cases Case Report The global COVID-19 vaccination had an undeniable influence on the pandemic management, despite of having reported rare but life-threatening side-effects of vaccines. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare autoimmune complication determined by thrombocytopenia and thrombosis propensity in the circulatory system. The activation of antibodies against platelet factor-4 (PF-4) which mimics the heparin-induced thrombocytopenia (HIT) characteristic is the main known pathogenicity of the disease. Herein, we reported a case of VITT in a middle-aged woman with no previous history of thrombophilia or other medical conditions who presented with thrombosis of the left superficial femoral artery 3-days after receiving the second dose of inactivated BBIBP-CorV (Sinopharm) vaccine. The patient underwent bypass vascular surgery and received none-heparin anticoagulation consistent with high-dose intravenous immunoglobin. Eight days after the discharge, she was subsequently referred to our center with the presentation of sub-massive pulmonary thromboembolism in spite of receiving the prophylactic anticoagulants during follow-up period. Details on side-effects of COVID-19 vaccines, specifically the inactivated ones are yet to be fully ascertained. Clinicians should consider the history of COVID-19 vaccines in thromboembolism patients who do not have well-acknowledged risk factors. Further studies about the necessity of prophylactic anticoagulants and clinical judgment for receiving other vaccines in such patients are required. UMF “Gr. T. Popa” Iasi Publishing House 2022-12-19 /pmc/articles/PMC9769072/ /pubmed/36628165 http://dx.doi.org/10.22551/2022.37.0904.10222 Text en https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Zaheri, Hamidreza
Kiani, Arda
Afaghi, Siamak
Rahimi, Fatemehsadat
Banitorfi, Mohammadhossein
Norozi, Amirmohammad Kazemzadeh
Hashemi, Samaneh
Abedini, Atefeh
Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination
title Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination
title_full Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination
title_fullStr Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination
title_full_unstemmed Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination
title_short Lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after Sinopharm BBIBP-CorV COVID-19 vaccination
title_sort lower limb arterial thrombosis followed by sub-massive pulmonary thromboembolism after sinopharm bbibp-corv covid-19 vaccination
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9769072/
https://www.ncbi.nlm.nih.gov/pubmed/36628165
http://dx.doi.org/10.22551/2022.37.0904.10222
work_keys_str_mv AT zaherihamidreza lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination
AT kianiarda lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination
AT afaghisiamak lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination
AT rahimifatemehsadat lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination
AT banitorfimohammadhossein lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination
AT noroziamirmohammadkazemzadeh lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination
AT hashemisamaneh lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination
AT abediniatefeh lowerlimbarterialthrombosisfollowedbysubmassivepulmonarythromboembolismaftersinopharmbbibpcorvcovid19vaccination